Chronic fatigue syndrome and arthralgia following parvovirus B19 infection

Journal of Rheumatology

Volumn 29, Issue 3, 2002, Pages 595-602

  Kerr, Jonathan R ^a   Bracewell, Janice ^a   Laing, Ian ^a   Mattey, Derek L ^a   Bernstein, Robert M ^a   Bruce, Ian N ^a   Tyrrell, David A J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Antinuclear antibody; Arthralgia; B19 viremia; Chronic fatigue syndrome; Fatigue; NS1 antibodies; Parvovirus B19; Rheumatoid factor

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; RHEUMATOID FACTOR;

ACUTE DISEASE; ADULT; AGE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; ERYTHEMA INFECTIOSUM; FEMALE; GENDER; HUMAN; IMMUNOFLUORESCENCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; SEROLOGY; SYMPTOMATOLOGY; VIREMIA; WESTERN BLOTTING;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, VIRAL; ARTHRALGIA; BIOLOGICAL MARKERS; CONVALESCENCE; FATIGUE SYNDROME, CHRONIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREDICTIVE VALUE OF TESTS; RHEUMATOID FACTOR; SEX DISTRIBUTION; VIREMIA;

EID: 0036192684     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Parvovirus-like particles in human sera
2. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia
3. Pathogenesis of human parvovirus B19 in rheumatic disease
4. Human parvovirus B19 infection is not followed by inflammatory joint disease during longterm follow-up. A retrospective study of 54 patients
5. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection
6. High frequency of parvovirus B19 in patients tested for rheumatoid factor
7. Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: Case history and review
8. Absence of parvovirus B19 infection in chronic fatigue syndrome
9. The chronic fatigue syndrome: A comprehensive approach to its definition and study
10. Parvovirus B19 and chronic fatigue syndrome
11. Design and production of a target-specific monoclonal antibody to parvovirus B19 capsid proteins
12. Multiple primer pairs for polymerase chain reaction amplification of human parvovirns parvovirus B19 DNA
13. Nucleotide sequence and genome organisation of human parvovirus B19 isolated from the serum of a child during aplastic crisis
14. Experimental parvoviral infection in humans
15. Parvovirus B19 clearance from peripheral blood after acute infection
16. Parvovirus B19 infection; persistence and genetic variation
17. Immune response to B19 parvovirus and an antibody defect in persistent viral infection
18. Seroprevalence of parvovirus B19 NS 1-specific IgG in B 19-infected and uninfected individuals and in infected pregnant women
19. Antibodies to parvovirus B19 NS1 protein in infected individuals
20. Antibodies to parvovirus B19 nonstructural protein are associated with chronic but not acute arthritis following B19 infection
21. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: Implication for pathogenesis
22. Mechanisms of parvovirus B19 persistence in peripheral blood mononuclear cells
23. Clinical significance of low-titer antinuclear antibodies in early rheumatoid arthritis: Implications for the presentation and long-term course of the disease
24. Fibromyalgia and parvovirus infection
25. Acute bilateral carpal tunnel syndrome associated with human parvovirus B 19 infection
26. Characterisation of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome
27. Chronic fatigue syndrome: Physical and cardiovascular deconditioning
28. Interconnection between thyroid hormone signalling pathways and parvovirus cytotoxic functions
29. Chronic fatigue syndrome: An update
30. Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illnesses: Elevated anti-early antigen antibodies
31. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection
32. Post-infection fatigue syndrome following Q fever
33. Systemic monocyte and T cell activation in a patient with human parvovirus B19 infection
34. Viral-associated haemophagocytosis and elevated serum TNF-α with parvovirus B19-related pancytopenia in patients with hereditary spherocytosis
35. Association of human parvovirus B19 infection with meningoencephalitis
36. Unusual clinical manifestations reported in patients with parvovirus B19 infection